Analysis: The growth of the Danish drug market
The development on the Danish drug market in the noughties and the current decade respectively could not be more different.
by Stefan Singh Kailay
In spite of a steady flow of new drugs against a number of diseases being launched in recent years, public bodies have managed to enforce a dramatic shift in the rise in drug costs. The basis is a tough stance from the Danish regions towards the drug industry due to budget tightening, and the stance has reduced yearly growth rates significantly.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
